Company: GIFLF
Filing Date: 2025-11-04
Form Type: 6-K
Source: 0001104659-25-106104
Chunk: 4

Company: Grifols SA
Filing Date: 2025-11-04
Form: 6-K
Chunk 4
---
ols.com

sostenibilidad@grifols.com- sustainability@grifols.com

Tel. +34 93 571 02 21

| 1 | Operating                                                                          
 or constant currency (cc) excludes changes rate variations reported in the period. |

| 2 | Calculated                                                                                    
 as EBITDA Adjusted - Net Working Capital - CAPEX (including capitalized IT and R&D, and       
 extraordinary growth CAPEX) - Others - Interest - Taxes. In the Consolidated Annual Accounts, 
 this reconciles to Cash flow generation from operating and inve sting activities excluding    
 impact from M&A and associated costs and expenses. Excludes lease payments, consistent        
 with prior disclosed guidance.                                                                |

| 3 | Guidance                                                                                     
 FX rate refers to FX rates as at 27 Feb 2025, consistent with page 38 of the Capital Markets 
 Day (CMD) presentation (EUR USD @ 1.04).                                                     |

Page 3 of 4

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well -being of people around the world. A leader in essential plasma -derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life -threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with close t o 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high -quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and